The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Colprone     (17S)-17-ethanoyl-6,10,13,17- tetramethyl-2...

Synonyms: Prothil, Colpro, Etogyn, MEDROGESTONE, Metrogestone, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of MEDROGESTONE

 

High impact information on MEDROGESTONE

 

Chemical compound and disease context of MEDROGESTONE

 

Biological context of MEDROGESTONE

 

Anatomical context of MEDROGESTONE

 

Associations of MEDROGESTONE with other chemical compounds

 

Gene context of MEDROGESTONE

  • Medrogestone has a biphasic effect on sulfotransferase activity in both cell lines [5].
  • This effect may be due to glucocorticoid receptor mediated actions of medrogestone on bone [16].
  • More 5 alpha-DHT was released into the medium from the testes mince in the presence of hCG, while the addition of 10 or 50 micrometers of Colprone inhibited 5 alpha-DHT release as compared to hCG controls [14].
  • Medrogestone had a synergistic effect on the lowering of FSH, LH and PRL [10].
  • RFA Argus, the Air Training Ship, was identified as the potential Primary Casualty Reception Ship (PCRS) and at the end of September 1990 plans were drawn up to convert the forward hangar into a two-storey 100-bed hospital in collective protection (COLPRO) [17].
 

Analytical, diagnostic and therapeutic context of MEDROGESTONE

  • After 24 h of the cell culture, Medrogestone significantly inhibits this transformation in a dose-dependent manner by 39% and 80% at 5 x 10(-8) M and 5 x 10(-5) M, respectively in T-47D cells; the effect is less intense in MCF-7 cells: 25% and 55% respectively [2].
  • Twenty patients, aged 30-60 yr, who had undergone bilateral ovariectomy, were treated orally with 5 mg medrogestone (6,17-dimethylpregna-4,6-diene-3,20-dione) and 1.25 mg conjugated oestrogens per day, according to a constant dosage pattern during the cycle (22 + 6 days) [18].
  • Determination of medrogestone in plasma by high-performance liquid chromatography [19].
  • The limit of quantitative concentration for medrogestone in HPLC was 1 ng/ml [19].
  • Argus arrived in the Gulf in mid-November as the PCRS with, all in COLPRO, a 10-bed intensive care unit (ICU), a 14-bed high dependency unit (HDU), a 76-bed low dependency unit (LDU) plus four operating tables in two theatres with full support services [17].

References

  1. Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia. Paulson, D.F., Kane, R.D. J. Urol. (1975) [Pubmed]
  2. Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. Chetrite, G.S., Ebert, C., Wright, F., Philippe, J.C., Pasqualini, J.R. J. Steroid Biochem. Mol. Biol. (1999) [Pubmed]
  3. Bone effects of transdermal hormone replacement therapy in postmenopausal women as evaluated by means of ultrasound: an open one-year prospective study. de Aloysio, D., Rovati, L.C., Cadossi, R., Paltrinieri, F., Mauloni, M., Mura, M., Penacchioni, P., Ventura, V. Maturitas. (1997) [Pubmed]
  4. Blood flow in the internal carotid and middle cerebral arteries: effects of continuous oral conjugated equine estrogens administration with monthly progestogen supplementation on postmenopausal women. Penotti, M., Sironi, L., Castiglioni, E., Miglierina, L., Barletta, L., Gabrielli, L., Vignali, M. Menopause (New York, N.Y.) (1999) [Pubmed]
  5. Control of sulfatase and sulfotransferase activities by medrogestone in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. Chetrite, G.S., Ebert, C., Wright, F., Philippe, A.C., Pasqualini, J.R. J. Steroid Biochem. Mol. Biol. (1999) [Pubmed]
  6. Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. Pasqualini, J.R., Chetrite, G.S. J. Steroid Biochem. Mol. Biol. (1999) [Pubmed]
  7. Progestins and breast cancer. Pasqualini, J.R., Paris, J., Sitruk-Ware, R., Chetrite, G., Botella, J. J. Steroid Biochem. Mol. Biol. (1998) [Pubmed]
  8. The effects of estradiol valerate plus medroxyprogesterone acetate and conjugated estrogens plus medrogestone on climacteric symptoms and metabolic variables in perimenopausal women. Egarter, C., Geurts, P., Boschitsch, E., Speiser, P., Huber, J. Acta obstetricia et gynecologica Scandinavica. (1996) [Pubmed]
  9. A comparison of oestrogen-progestogen with clonidine in the climacteric syndrome. Sonnendecker, E.W., Polakow, E.S. S. Afr. Med. J. (1980) [Pubmed]
  10. Effects of conjugated equine oestrogens with and without the addition of cyclical medrogestone on hot flushes, liver function, blood pressure and endocrinological indices. Sonnendecker, E.W., Polakow, E.S. S. Afr. Med. J. (1990) [Pubmed]
  11. Sequential addition of low dose of medrogestone or medroxyprogesterone acetate to transdermal estradiol: a pilot study on their influence on the endometrium. Pansini, F., De Paoli, D., Albertazzi, P., Bonaccorsi, G., Campobasso, C., Zanotti, L., Pisati, R., Giulini, N.A. Eur. J. Obstet. Gynecol. Reprod. Biol. (1996) [Pubmed]
  12. Differences in the mechanism of action of medrogestone and cyproterone acetate. Sufrin, G., Coffey, D.S. Investigative urology. (1975) [Pubmed]
  13. The effect of medrogestone on plasma lipids and lipoproteins in postmenopausal women using conjugated estrogens: an open randomized comparative study. Gevers Leuven, J.A., van der Mooren, M.J., Buytenhek, R. Fertil. Steril. (1995) [Pubmed]
  14. Effects of Colprone on in vitro release of androgens from the reproductive organs of the male rat. Lau, I.F., Saksena, S.K. Int. J. Androl. (1981) [Pubmed]
  15. Hormone replacement therapy and estrogen-dependent cancers. Birkhäuser, M. International journal of fertility and menopausal studies. (1994) [Pubmed]
  16. Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Sillem, M., Parviz, M., Woitge, H.W., Kiesel, L., Ulrich, U., von Holst, T., Runnebaum, B., Ziegler, R., Seibel, M.J. Exp. Clin. Endocrinol. Diabetes (1999) [Pubmed]
  17. Primary Casualty Reception Ship: the hospital within--Operation Granby. Dewar, E.P. Journal of the Royal Naval Medical Service. (1992) [Pubmed]
  18. Effects of medrogestone and conjugated oestrogens on serum lipid and lipoprotein concentrations. Teichmann, A.T., Wieland, H., Cremer, P., Hinney, B., Kuhn, W., Seidel, D. Maturitas. (1985) [Pubmed]
  19. Determination of medrogestone in plasma by high-performance liquid chromatography. Lin, W.J., Her, S.J., Chen, P.F., Chen, R.R. J. Chromatogr. B Biomed. Sci. Appl. (1998) [Pubmed]
 
WikiGenes - Universities